Ofatumumab added to dexamethasone in patients with relapsed or refractory chronic lymphocytic leukemia: Results from a phase II study

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11150%2F15%3A10295097" target="_blank" >RIV/00216208:11150/15:10295097 - isvavai.cz</a>

Alternative codes found

RIV/00216224:14740/15:00082873 RIV/65269705:_____/15:00063759 RIV/00179906:_____/15:10295097 RIV/00064165:_____/15:10295097

Result on the web

<a href="http://dx.doi.org/10.1002/ajh.23964" target="_blank" >http://dx.doi.org/10.1002/ajh.23964</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1002/ajh.23964" target="_blank" >10.1002/ajh.23964</a>

Result language

angličtina

Original language name

Ofatumumab added to dexamethasone in patients with relapsed or refractory chronic lymphocytic leukemia: Results from a phase II study

Original language description

The treatment of relapsed/refractory chronic lymphocytic leukemia (CLL) remains a challenging clinical issue. An important treatment option is the use of high-dose corticosteroids. The purpose of this clinical trial was to determine the efficacy and toxicity of an ofatumumab-dexamethasone (O-Dex) combination in relapsed or refractory CLL. The trial was an open-label, multicenter, nonrandomized, Phase II study. The O-Dex regimen consisted of intravenous ofatumumab (Cycle 1: 300 mg on day 1, 2,000 mg on days 8, 15, and 22; Cycles 2-6: 1,000 mg on days 1, 8, 15, and 22) and oral dexamethasone (40 mg on days 1-4 and 15-18; Cycles 1-6). The O-Dex regimen was given until best response, or a maximum of six cycles. Thirty-three patients (pts) were recruited. Twenty-four (73%) pts completed at least three cycles of therapy. The remaining nine pts were prematurely discontinued owing to Grade 3/4 infections (seven pts), disease progression (one pt), or uncontrollable diabetes mellitus (one pt). O

Czech name

—

Czech description

—

Type

J_x - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)

CEP classification

FD - Oncology and haematology

OECD FORD branch

—

Project

—

Continuities

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Publication year

2015

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Name of the periodical

American Journal of Hematology

ISSN

0361-8609

e-ISSN

—

Volume of the periodical

90

Issue of the periodical within the volume

5

Country of publishing house

US - UNITED STATES

Number of pages

5

Pages from-to

417-421

UT code for WoS article

000353393300020

EID of the result in the Scopus database

2-s2.0-84928295165